We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Sage Therapeutics Stock Up on SAGE-547 Regulatory Update
Read MoreHide Full Article
Shares of Sage Therapeutics, Inc. (SAGE - Free Report) gained 7.5% after the company announced its expedited development plan for SAGE-547 following the receipt of formal meeting minutes from a breakthrough therapy meeting with the FDA.
A look at the company’s year-to-day share price movement shows that the stock has outperformed the Zacks classified Medical Drug industry. The stock’s price declined 4.5% in the year-to-date period, which compared favorably to the 25.2% decline for the industry.
Coming back to the latest news, the program is intended to support a potential filing (anticipated in 2018) for SAGE-547 for the treatment of postpartum depression (PPD).
Note that Sage Therapeutics initiated an expansion of the phase III clinical program on SAGE-547, following positive top-line results from a phase II 202A study. The study will evaluate dose ranges of the candidate in severe PPD patients and evaluate its efficacy in patients with moderate PPD.
The company reported that it will modify the phase III study, including an increase in sample size, to facilitate global registration. Top-line data are anticipated in the second half 2017.
We remind investors that in Sep 2016, SAGE-547 was granted Breakthrough Therapy Designation in the U.S. for PPD. Moreover, in November, the candidate received PRIority MEdicines (PRIME) designation from the European Medicines Agency (EMA).
PPD, an affective disorder impacting women after childbirth, is estimated to occur in 500,000 to 750,000 mothers in the U.S. each year.
Meanwhile, Sage Therapeutics is studying SAGE-547 for other indications as well. The company is currently enrolling patients in a phase III study – STATUS – to evaluate the safety and efficacy of SAGE-547 for the treatment of patients with super-refractory status epilepticus.
Sage Therapeutics carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector are Sucampo Pharmaceuticals, Inc. , Cambrex Corporation and Vanda Pharmaceuticals, Inc. (VNDA - Free Report) . Each stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Sucampo’s earnings estimates increased from $1.03 to $1.22 for 2016 and from $1.30 to $1.58 for 2017 over the last 60 days. The company posted a positive surprise in all of the four trailing quarters with an average beat of 35.55%.
Cambrex’s earnings estimates increased from $2.46 to $2.55 for 2016 and from $2.91 to $3.06 for 2017 over the last 60 days. The company posted a positive earnings surprise in three of the four trailing quarters with an average beat of 19.78%.
Vanda’s loss estimates narrowed from 62 cents to 52 cents for 2016, while its earnings estimates increased from 13 cents to 22 cents for 2017 over the last 60 days. The company posted a positive earnings surprise in three of the four trailing quarters with an average beat of 56.65%.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Sage Therapeutics Stock Up on SAGE-547 Regulatory Update
Shares of Sage Therapeutics, Inc. (SAGE - Free Report) gained 7.5% after the company announced its expedited development plan for SAGE-547 following the receipt of formal meeting minutes from a breakthrough therapy meeting with the FDA.
A look at the company’s year-to-day share price movement shows that the stock has outperformed the Zacks classified Medical Drug industry. The stock’s price declined 4.5% in the year-to-date period, which compared favorably to the 25.2% decline for the industry.
Coming back to the latest news, the program is intended to support a potential filing (anticipated in 2018) for SAGE-547 for the treatment of postpartum depression (PPD).
Note that Sage Therapeutics initiated an expansion of the phase III clinical program on SAGE-547, following positive top-line results from a phase II 202A study. The study will evaluate dose ranges of the candidate in severe PPD patients and evaluate its efficacy in patients with moderate PPD.
The company reported that it will modify the phase III study, including an increase in sample size, to facilitate global registration. Top-line data are anticipated in the second half 2017.
We remind investors that in Sep 2016, SAGE-547 was granted Breakthrough Therapy Designation in the U.S. for PPD. Moreover, in November, the candidate received PRIority MEdicines (PRIME) designation from the European Medicines Agency (EMA).
PPD, an affective disorder impacting women after childbirth, is estimated to occur in 500,000 to 750,000 mothers in the U.S. each year.
Meanwhile, Sage Therapeutics is studying SAGE-547 for other indications as well. The company is currently enrolling patients in a phase III study – STATUS – to evaluate the safety and efficacy of SAGE-547 for the treatment of patients with super-refractory status epilepticus.
SAGE THERAPEUTC Price and Consensus
SAGE THERAPEUTC Price and Consensus | SAGE THERAPEUTC Quote
Zacks Rank & Key Picks
Sage Therapeutics carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector are Sucampo Pharmaceuticals, Inc. , Cambrex Corporation and Vanda Pharmaceuticals, Inc. (VNDA - Free Report) . Each stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Sucampo’s earnings estimates increased from $1.03 to $1.22 for 2016 and from $1.30 to $1.58 for 2017 over the last 60 days. The company posted a positive surprise in all of the four trailing quarters with an average beat of 35.55%.
Cambrex’s earnings estimates increased from $2.46 to $2.55 for 2016 and from $2.91 to $3.06 for 2017 over the last 60 days. The company posted a positive earnings surprise in three of the four trailing quarters with an average beat of 19.78%.
Vanda’s loss estimates narrowed from 62 cents to 52 cents for 2016, while its earnings estimates increased from 13 cents to 22 cents for 2017 over the last 60 days. The company posted a positive earnings surprise in three of the four trailing quarters with an average beat of 56.65%.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>